Targeted therapy database (TTD): A model to match patient's molecular profile with current knowledge on cancer biology

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Mocellin, Simone ^a   Shrager, Jeff ^b   Scolyer, Richard ^c,d,e   Pasquali, Sandro ^a   Verdi, Daunia ^a   Marincola, Francesco M ^f   Briarava, Marta ^a   Gobbel, Randy ^b   Rossi, Carlo ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b STANFORD UNIVERSITY   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ALGORITHM; CANCER PATIENT; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CYTOLOGY; DATA BASE; HUMAN; KNOWLEDGE BASE; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL COMPUTING; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR MODEL; NONHUMAN; PATIENT INFORMATION; PREDICTION; REVIEW; TARGETED THERAPY DATABASE; ARTICLE; BIOLOGICAL MODEL; BIOLOGY; COMPUTER SIMULATION; DRUG RESISTANCE; EVIDENCE BASED MEDICINE; INFORMATION PROCESSING; METABOLISM; NEOPLASM; PERSONALIZED MEDICINE;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATA COLLECTION; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; MELANOMA; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 77957837728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011965     Document Type: Review

References (56)

1. World Health Organization (2004) Mortality and health status: causes of deathdatabase.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.CA Cancer J Clin 59: 225-249.
3. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, et al. (2009) Fulfilling the promise of personalized medicine? Systematic review and fieldsynopsis of pharmacogenetic studies. PLoS One 4: e7960.
4. Riley LB, Desai DC (2009) The molecular basis of cancer and the developmentof targeted therapy. Surg Clin North Am 89: 1-15, 7.
5. Allgayer H, Fulda S (2008) An introduction to molecular targeted therapy ofcancer. Adv Med Sci 53: 130-138.
6. Chabner BA, Roberts TG, Jr. (2005) Timeline: Chemotherapy and the war oncancer. Nat Rev Cancer 5: 65-72.
7. van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicinethrough analysis of gene-expression patterns. Nature 452: 564-570.
8. Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CACancer J Clin 59: 111-137.
9. Burke W, Psaty BM (2007) Personalized medicine in the era of genomics. Jama298: 1682-1684.
10. Ely S (2009) Personalized medicine: individualized care of cancer patients Transl Res 154: 303-308.
11. Ginsburg GS, Willard HF (2009) Genomic and personalized medicine:foundations and applications. Transl Res 154: 277-287.
12. Parkinson DR, Ziegler J (2009) Educating for personalized medicine: aperspective from oncology. Clin Pharmacol Ther 86: 23-25.
13. Frueh FW (2009) Back to the future: why randomized controlled trials cannot bethe answer to pharmacogenomics and personalized medicine. Pharmacogenomics10: 1077-1081.
14. Gomah ME, Turley JP, Lu H, Jones D (2010) Modeling complex workflow inmolecular diagnostics: design specifications of laboratory software for support ofpersonalized medicine. J Mol Diagn 12: 51-57.
15. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapiesfor cancer. Nat Rev Cancer 6: 714-727.
16. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathwaysignatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
17. Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospectsfor antibodies and immunoconjugates. CA Cancer J Clin 56: 226-243.
18. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years ofprogress. Nat Rev Cancer 8: 473-480.
19. Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, et al. (2009) ClinicalCancer Advances 2009: major research advances in cancer treatment,prevention, and screening-a report from the American Society of ClinicalOncology. J Clin Oncol 27: 6052-6069.
20. Janne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers tosmall-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
21. McDermott U, Settleman J (2009) Personalized cancer therapy with selectivekinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 27:5650-5659.
22. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome throughpolypharmacology. Nat Rev Cancer 10: 130-137.
23. McConnell P, Dash RC, Chilukuri R, Pietrobon R, Johnson K, et al. (2008) Thecancer translational research informatics platform. BMC Med Inform DecisMak 8: 60.
24. Payne PR, Borlawsky TB, Kwok A, Greaves AW (2008) Supporting the design oftranslational clinical studies through the generation and verification of conceptualknowledge-anchored hypotheses. AMIA Annu Symp Proc. pp 566-570.
25. Stokes TH, Torrance JT, Li H, Wang MD (2008) ArrayWiki: an enablingtechnology for sharing public microarray data repositories and meta-analyses.BMC Bioinformatics 9 Suppl 6: S18.
26. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, et al. (2010) TheUCSC Genome Browser database: update 2010. Nucleic Acids Res 38:D613-619.
27. Ficenec D, Osborne M, Pradines J, Richards D, Felciano R, et al. (2003) Computational knowledge integration in biopharmaceutical research. BriefBioinform 4: 260-278.
28. Rodriguez H, Snyder M, Uhlen M, Andrews P, Beavis R, et al. (2009) Recommendations from the 2008 International Summit on Proteomics DataRelease and Sharing Policy: the Amsterdam principles. J Proteome Res 8:3689-3692.
29. Amin W, Kang HP, Egloff AM, Singh H, Trent K, et al. (2009) An informaticssupported web-based data annotation and query tool to expedite translationalresearch for head and neck malignancies. BMC Cancer 9: 396.
30. Krallinger M, Rojas AM, Valencia A (2009) Creating reference datasets forsystems biology applications using text mining. Ann N Y Acad Sci 1158: 14-28.
31. Kreeger PK, Lauffenburger DA (2010) Cancer systems biology: a networkmodeling perspective. Carcinogenesis 31: 2-8.
32. Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, et al. (2009) Asystems biology view of cancer. Biochim Biophys Acta 1796: 129-139.
33. Pharm GKB (2010) Pharmacogenomics Knowledge Base.
34. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) TheConnectivity Map: using gene-expression signatures to connect small molecules,genes, and disease. Science 313: 1929-1935.
35. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. NatRev Drug Discov 7: 900-907.
36. Zhu F, Han B, Kumar P, Liu X, Ma X, et al. (2010) Update of TTD:Therapeutic Target Database. Nucleic Acids Res 38: D787-791.
37. Kanehisa M (2009) Representation and analysis of molecular networks involvingdiseases and drugs. Genome Inform 23: 212-213.
38. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank:a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901-906.
39. Fang X, Shao L, Zhang H, Wang S (2004) Web-based tools for mining the NCIdatabases for anticancer drug discovery. J Chem Inf Comput Sci 44: 249-257.
40. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma.N Engl J Med 351: 998-1012.
41. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet365: 687-701.
42. Wang SQ, Halpern AC (2007) Management of cutaneous melanoma: a publichealth and individual patient care perspective. Adv Dermatol 23: 81-98.
43. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasingburden of melanoma in the United States. J Invest Dermatol 129: 1666-1674.
44. Tawbi HA, Kirkwood JM (2007) Management of metastatic melanoma. SeminOncol 34: 532-545.
45. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, et al. (2007) Treatments for metastatic melanoma: synthesis of evidence from randomizedtrials. Cancer Treat Rev 33: 665-680.
46. Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastaticmelanoma: time for a change? Cancer 109: 455-464.
47. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, et al. (2004) Anevidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131-149; quiz 182-134.
48. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC (2008) Adjuvant therapywith high-dose interferon alpha 2b in patients with high-risk stage IIB/IIImelanoma. Nat Clin Pract Oncol 5: 2-3.
49. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon Alpha AdjuvantTherapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst.
50. Mocellin S, Rossi CR (2008) The melanoma molecular map project. MelanomaRes 18: 163-165.
51. Higgins JPT, Green S (2009) Cochrane Handbook for Systematic Reviews: www.cochrane-handbook.org (CochraneCollaborationwebsite, last access: February 2010).
52. Sutton AJ, Higgins JP (2008) Recent developments in meta-analysis. Stat Med27: 625-650.
53. Macleod MR, Ebrahim S, Roberts I (2005) Surveying the literature from animalexperiments: systematic review and meta-analysis are important contributions.Bmj 331: 110.
54. Normand SL (1999) Meta-analysis: formulating, evaluating, combining, andreporting. Stat Med 18: 321-359.
55. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J (2005) A method formeta-analysis of molecular association studies. Stat Med 24: 1291-1306.
56. Kavvoura FK, Ioannidis JP (2008) Methods for meta-analysis in geneticassociation studies: a review of their potential and pitfalls. Hum Genet 123:1-14.